Avishay Bransky, CEO of PixCell Medical, discusses its new FDA-cleared platform.
What has PixCell Medical developed?
PixCell Medical has developed an FDA-cleared platform intended for use at the Point-Of-Care (POC) that can deliver lab-quality full five-part differential Complete Blood Count (CBC) results and comprehensive abnormal cell flagging. PixCell’s HemoScreen diagnostic platform shortens diagnostic results delivery from days to minutes. With just one drop of blood and within six minutes, PixCell delivers accurate readings of 20 standard blood count parameters, saving patients, clinicians and health systems significant time and costs. The HemoScreen analyzer requires no maintenance or calibration, making it ideal for use at the POC. CBC tests accessible at the POC can enable early detection of many serious health issues.
How is this different to other blood diagnostic devices?
Other blood diagnostic devices on the market use imaging, as PixCell does, but they use a chip and not a cartridge. PixCell has lab-on-a-cartridge technology, and this is where its innovation lies. The standard practice is flow cytometry, but PixCell combines flow and imaging cytometry. The cartridge automatically prepares a sample, simplifying the whole blood testing process.
When did this device gain FDA clearance?
In November 2018.
How will this technology be used in the future?
We will soon be facing a "new world" when we reach the other side of the pandemic that will require developing new diagnostics assays and having a single platform that can be used for various tests. If we can make testing more accessible, people everywhere can gain better healthcare services, and we can potentially manage future outbreaks more efficiently to save lives.